Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heat zaps pancreatic growths without cutting

NCT ID NCT07536087

Disease control Sponsor: Institute for Clinical and Experimental Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a procedure called EUS-RFA, which uses a thin tube with a camera and a tiny heat probe to destroy pancreatic cysts and small tumors. It is for people who cannot have surgery or choose not to. The goal is to shrink or eliminate these growths, reduce the need for frequent scans, and lower the risk of complications from surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consensual indication to EUS-guided RFA treatment made in a multidisciplinary team * Capability of giving informed consent PCN Inoperability or refusal of surgery * Branch duct IPMN (BD-IPMN) with worrisome features: * Jaundice * High grade dysplasia or cancer * Solid mass/nodule \> 5mm * Main pancreatic duct dilation \> 10mm Or at least one (patients without comorbidities) or at least two (patient with comorbidities) of the following risk features: * CA 19-9\> 37 U/ml * Increase in size \> 5mm/year * Dilation of the main pancreatic duct between 5-10mm * Size ≥ 40mm * Symptoms (new onset of diabetes, acute pancreatitis) * Nodule \< 5mm Pancreatic NET * Size \< 2 cm * Histological proof in non-functional lesions/histological proof or clinical proof in functional lesions * 68Ga-DOTATATE PET/CT positive for a pancreatic lesion and negative for lymph nodes, liver, and other distant metastases * G1 or G2 (\<5 %) histology Exclusion Criteria: * Known bleeding disorder that cannot be sufficiently corrected with medication * Use of anticoagulants that cannot be discontinued * Physical and/or psychological inability to understand the aims of the research and to adequately cooperate * Pregnancy * Inability to sign the informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endoscopic ultrasound-guided radiofrequency ablation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystic tumor of the pancreas neuroendocrine neoplasm pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endoscopic ultrasound-guided radiofrequency ablation Pancreatic cystic neoplasms Pancreatic neuroendocrine tumors (PNET)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute for Clinical and Experimental Medicine, Department of Gastroenterology and Hepatology

    RECRUITING

    Prague, 140 21, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.